Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director | August 18, 2026 | August 20, 2026 |
| SELLAS Life Sciences Group, Inc.GALE · Entity 4313 | Director | October 10, 2017 | October 10, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,499 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Exercise / conversion · Acquired 6,107 · Balance 28,499 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 44,790 |
Reported balance
After 2026-08-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-18 · Exercise / conversion · Disposed 6,107 · Balance 44,790 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2025; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2025; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter.
SELLAS Life Sciences Group, Inc.
Report date October 10, 2017 · Filed October 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,339 |
Reported balance
After 2017-10-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-10-10 · Grant · Acquired 12,708 · Balance 31,339 F1: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.
F2: Represents the closing stock price of the Company's stock on the first trading day of the quarter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kindred Biosciences, Inc.
Report date August 27, 2021 · Filed August 31, 2021
Section 16 reporting ended · disclosed 2021-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 1
1 source rowRow 1 · 2021-08-27 · Disposition to issuer · Disposed 1,709,271 · Balance 0 F1: Represents 1,709,271 shares of common stock that were disposed of at the effective time of the merger (the "Merger") contemplated by the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $9.25 per share. Certain of these securities were restricted stock units ("RSUs") that represented the reporting person's right to receive the Kindred Biosciences, Inc.'s common stock. Pursuant to the Merger Agreement, the RSUs were subject to acceleration of vesting, cancelled and converted automatically into the right to receive a cash payment of $9.25 per share, subject to any required withholding of taxes. |
| Common StockSEC Table I · non-derivative | IndirectBy reporting person as custodian for son | 0 |
Reported balance
After 2021-08-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy reporting person as custodian for son | 0 |
Reported balance
After 2021-08-27 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy reporting person as custodian for daughter | 0 |
Reported balance
After 2021-08-27 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy reporting person as custodian for daughter | 0 |
Reported balance
After 2021-08-27 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2021-08-27 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2023-02-04 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-27 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: This option, which vested 25% of the total number of shares underlying the option ("Option Shares") on the annual anniversary of February 4, 2013, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $3,556,000, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.52 · Expires 2024-02-04 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-08-27 · Disposition to issuer · Disposed 350,000 · Balance 0 F4: This option, which vested 25% of the Option Shares on the annual anniversary of February 4, 2014, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2025-02-05 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-08-27 · Disposition to issuer · Disposed 197,771 · Balance 0 F5: This option, which vested 25% of the Option Shares on the annual anniversary of February 5, 2015, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $551,781.09, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2026-01-08 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-08-27 · Disposition to issuer · Disposed 197,771 · Balance 0 F6: This option, which vested 25% of the Option Shares on the annual anniversary of January 8, 2016, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,147,071.80, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2027-01-23 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-08-27 · Disposition to issuer · Disposed 175,000 · Balance 0 F7: This option, which vested 25% of the Option Shares on the annual anniversary of January 23, 2017, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $498,750.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.75 · Expires 2028-01-22 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-08-27 · Disposition to issuer · Disposed 175,000 · Balance 0 F8: This option vested 25% of the Option Shares on the annual anniversary of January 22, 2018, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $87,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.91 · Expires 2029-01-31 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-08-27 · Disposition to issuer · Disposed 400,000 · Balance 0 F9: This option vested 25% of the Option Shares on the annual anniversary of February 1, 2019, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.84 · Expires 2030-01-16 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-08-27 · Disposition to issuer · Disposed 300,000 · Balance 0 F10: This option vested 25% of the Option Shares on the annual anniversary of January 17, 2020, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2031-01-19 | Direct | 0 |
Reported balance
After 2021-08-27 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-08-27 · Disposition to issuer · Disposed 394,000 · Balance 0 F11: This option provided for vesting of 25% of the Option Shares on the annual anniversary of January 20, 2021, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,895,140.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 1,709,271 shares of common stock that were disposed of at the effective time of the merger (the "Merger") contemplated by the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $9.25 per share. Certain of these securities were restricted stock units ("RSUs") that represented the reporting person's right to receive the Kindred Biosciences, Inc.'s common stock. Pursuant to the Merger Agreement, the RSUs were subject to acceleration of vesting, cancelled and converted automatically into the right to receive a cash payment of $9.25 per share, subject to any required withholding of taxes.
F2: Disposed of pursuant to the Merger Agreement in exchange for cash payment of $9.25 per share.
F3: This option, which vested 25% of the total number of shares underlying the option ("Option Shares") on the annual anniversary of February 4, 2013, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $3,556,000, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F4: This option, which vested 25% of the Option Shares on the annual anniversary of February 4, 2014, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F5: This option, which vested 25% of the Option Shares on the annual anniversary of February 5, 2015, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $551,781.09, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F6: This option, which vested 25% of the Option Shares on the annual anniversary of January 8, 2016, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,147,071.80, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F7: This option, which vested 25% of the Option Shares on the annual anniversary of January 23, 2017, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued employment on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $498,750.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F8: This option vested 25% of the Option Shares on the annual anniversary of January 22, 2018, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $87,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F9: This option vested 25% of the Option Shares on the annual anniversary of February 1, 2019, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F10: This option vested 25% of the Option Shares on the annual anniversary of January 17, 2020, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F11: This option provided for vesting of 25% of the Option Shares on the annual anniversary of January 20, 2021, with the remaining Option Shares vesting in equal monthly installments over the following three years, subject to continued employment on each such vesting date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1,895,140.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2020 Filed Jan 23, 2020 01:46 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001250853-20-000030 · primary_doc.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock. F3 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments following the date of grant. F3 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments following the date of grant. Read SEC document |
| January 17, 2020 Filed Jan 23, 2020 01:46 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $9.84 | $0.00 |
DisclosureSEC source: 0001250853-20-000030 · primary_doc.xml · derivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-01-16 F1 · derivative.exercise_date: The option will vest as to 25% after one year following the date of grant, and the remainder will vest in 36 equal monthly installments over the following three years. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:25 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001250853-19-000046 · primary_doc.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock. F3 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments following the date of grant. F3 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments following the date of grant. Read SEC document |
| February 01, 2019 Filed Feb 6, 2019 00:25 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0001250853-19-000046 · primary_doc.xml · derivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-01-31 F1 · derivative.exercise_date: The option will vest as to 25% after one year following the date of grant, and the remainder will vest in 36 equal monthly installments over the following three years. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 02:56 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | Tax withholdingCommon Stock | 8,646 | $9.95 | $85,984.47 |
DisclosureSEC source: 0001250853-19-000036 · primary_doc.xml · nonDerivative · entry 3 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,921,957 F2 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 02:56 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001250853-19-000036 · primary_doc.xml · derivative · entry 4 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 22, 2018, the reporting person was granted 150,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On January 22, 2018, the reporting person was granted 150,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 02:56 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | Tax withholdingCommon Stock | 12,968 | $10.12 | $131,236.16 |
DisclosureSEC source: 0001250853-19-000036 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930,603 F2 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 02:56 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | Exercise / conversionCommon Stock | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001250853-19-000036 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,943,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 02, 2019 Filed Jan 5, 2019 01:41 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCommon Stock | 40,000 | $10.57 | $422,716.00 |
DisclosureSEC source: 0001250853-19-000020 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $10.91, inclusive. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 00:00 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCommon Stock | 40,000 | $13.28 | $531,200.00 |
DisclosureSEC source: 0001250853-18-000145 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $13.68, inclusive. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 23:47 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 40,000 | $14.68 | $587,200.00 |
DisclosureSEC source: 0001250853-18-000137 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,986,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.09 to $14.90, inclusive. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:15 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCommon Stock | 40,000 | $13.28 | $531,200.00 |
DisclosureSEC source: 0001250853-18-000126 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,026,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.94 to $13.86, inclusive. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 00:07 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 7,600 | $14.69 | $111,644.00 |
DisclosureSEC source: 0001250853-18-000121 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,066,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.55 to $14.80, inclusive. Read SEC document |
| September 04, 2018 Filed Sep 7, 2018 00:07 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 32,400 | $14.81 | $479,844.00 |
DisclosureSEC source: 0001250853-18-000121 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,073,671 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.75 to $14.95, inclusive. Read SEC document |
| August 01, 2018 Filed Aug 4, 2018 01:06 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCommon Stock | 40,000 | $13.51 | $540,400.00 |
DisclosureSEC source: 0001250853-18-000111 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,106,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.40 to $13.80, inclusive. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 21:57 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCommon Stock | 40,000 | $10.28 | $411,200.00 |
DisclosureSEC source: 0001250853-18-000095 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,146,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.05 to $10.50, inclusive. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 23:07 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 40,000 | $10.13 | $405,200.00 |
DisclosureSEC source: 0001250853-18-000079 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,186,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.35, inclusive. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 23:07 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 12,610 | $10.00 | $126,100.00 |
DisclosureSEC source: 0001250853-18-000079 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,226,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.05, inclusive. Read SEC document |
| May 25, 2018 Filed May 29, 2018 23:48 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 3,000 | $10.00 | $30,000.00 |
DisclosureSEC source: 0001250853-18-000078 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,238,681 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. Read SEC document |
| May 24, 2018 Filed May 29, 2018 23:48 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 60 | $10.00 | $600.00 |
DisclosureSEC source: 0001250853-18-000078 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,241,681 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. Read SEC document |
| May 18, 2018 Filed May 18, 2018 22:35 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 2,400 | $10.00 | $24,000.00 |
DisclosureSEC source: 0001250853-18-000077 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,241,741 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017 Read SEC document |
| May 09, 2018 Filed May 9, 2018 23:28 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 200 | $10.00 | $2,000.00 |
DisclosureSEC source: 0001250853-18-000074 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,244,141 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. Read SEC document |
| May 07, 2018 Filed May 9, 2018 23:28 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCOMMON STOCK | 1,730 | $10.01 | $17,317.30 |
DisclosureSEC source: 0001250853-18-000074 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,244,341 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.15, inclusive. Read SEC document |
| May 01, 2018 Filed May 3, 2018 00:34 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCommon Stock | 20,000 | $9.05 | $181,000.00 |
DisclosureSEC source: 0001250853-18-000070 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,246,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.95 to $9.25, inclusive. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 23:08 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCommon Stock | 20,000 | $8.39 | $167,800.00 |
DisclosureSEC source: 0001250853-18-000055 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,266,071 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.20 to $8.65, inclusive. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 01:24 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | Tax withholdingCommon Stock | 11,475 | $9.15 | $104,996.25 |
DisclosureSEC source: 0001250853-18-000028 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,286,071 F4 · shares: These shares are being surrendered to satisfy a tax withholding obligation of the reporting person. Read SEC document |
| January 22, 2018 Filed Jan 25, 2018 01:24 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001250853-18-000028 · primary_doc.xml · derivative · entry 3 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock. F3 · derivative.exercise_date: The option will vest as to 25% annually following the date of grant. F3 · derivative.expiration_date: The option will vest as to 25% annually following the date of grant. Read SEC document |
| January 22, 2018 Filed Jan 25, 2018 01:24 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0001250853-18-000028 · primary_doc.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Commmon Stock · 175,000 shares Expires 2028-01-22 F1 · derivative.exercise_date: The option will vest as to 25% after one year following the date of grant, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 21:45 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 12,708 | $0.38 | $4,829.04 |
DisclosureSEC source: 0001394548-17-000027 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,339 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 06, 2017 Filed Jul 6, 2017 21:30 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 8,104 | $0.59 | $4,781.36 |
DisclosureSEC source: 0001394548-17-000022 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,631 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 21:50 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCommon Stock | 13,000 | $8.26 | $107,380.00 |
DisclosureSEC source: 0001250853-17-000060 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,297,546 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.15 to $8.65, inclusive. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2017. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 11:42 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | SaleCommon Stock | 13,000 | $7.75 | $100,750.00 |
DisclosureSEC source: 0001250853-17-000058 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,310,546 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2017. Read SEC document |
| June 08, 2017 Filed Jul 6, 2017 21:30 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001394548-17-000022 · primary_doc.xml · derivative · entry 2 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-08 F3 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F4 · derivative.exercise_date: This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:56 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 8,107 | $0.59 | $4,783.13 |
DisclosureSEC source: 0001394548-17-000013 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,527 F1 · security: Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| January 23, 2017 Filed Jan 26, 2017 01:23 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001250853-17-000022 · primary_doc.xml · derivative · entry 3 Chin Richard · CIK 0001337252 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-01-23 F2 · derivative.exercise_date: The option will vest as to 25% after one year following the date of grant, and the remainder will vest in equal monthly installments over the following three years. Read SEC document |
| January 23, 2017 Filed Jan 26, 2017 01:23 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001250853-17-000022 · primary_doc.xml · nonDerivative · entry 2 Chin Richard · CIK 0001337252 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,323,546 Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 23:00 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantCommon Stock | 2,420 | $1.98 | $4,791.60 |
DisclosureSEC source: 0001394548-17-000005 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,420 F1 · security: Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter. F2 · price: Represents the closing stock price of the Company's stock on the first trading day of the quarter. Read SEC document |
| May 17, 2016 Filed Jan 26, 2017 01:23 UTC | Kindred Biosciences, Inc. KIN · Entity 135544 | GiftCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001250853-17-000022 · primary_doc.xml · nonDerivative · entry 1 Chin Richard · CIK 0001337252 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,223,546 F1 · kind: This transaction involved a gift of securities by the reporting person to a family trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.